SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ – ESSA Pharma Inc. (NASDAQ: EPIX) (“ESSA” or the “Company”) is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all […]
Tag: ESSA Pharma Inc
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Efficacy signals observed will not achieve ESSA’s target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, […]
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ – ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, […]
